Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXK6EI)

Drug Name

FM-101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin 6 receptor (IL6R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tocilizumab	DM7J6OR	Giant cell arteritis	4A44.2	Approved	[2]
Sarilumab	DMOGNXY	Rheumatoid arthritis	FA20	Approved	[3]
Sirukumab	DMK8AQP	Cutaneous lupus erythematosus	EB5Z	Phase 3	[1]
SAR153191	DMXAO4J	Ankylosing spondylitis	FA92.0	Phase 3	[4]
SA-237	DM7F2VG	Encephalopathy	8E47	Phase 3	[5]
Vobarilizumab	DM9KNJT	Rheumatoid arthritis	FA20	Phase 2	[6]
ALX-0061	DMO1VHC	Autoimmune diabetes	5A10	Phase 2	[7]
SBP-002	DM9F7R0	Melanoma	2C30	Terminated	[3]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[8]
Sant7	DM9CV4P	Multiple myeloma	2A83	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
2	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
5	IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.
6	Clinical pipeline report, company report or official report of Ablynx.
7	The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.
8	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.